17Sep/13

Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification … – Sacramento Bee

Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification
Sacramento Bee
40 4.5.3 Laquinimod (laquinimod sodium) – Teva Pharmaceuticals 41 4.5.4 ocrelizumab – F. Hoffman-La Roche 42 4.5.5 daclizumab – Biogen Idec and Abbot Laboratories 42 4.5.6 firategrast – GlaxoSmithKline 43 4.5.7 Siponimod (BAF-312) – Novartis AG 

and more »

16Sep/13

Immune system marker tied to improved bone marrow transplant outcomes – Science Daily (press release)

Immune system marker tied to improved bone marrow transplant outcomes
Science Daily (press release)
16, 2013 — The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude 
Bone marrow donation touted as a lifesaverChicago Tribune

all 3 news articles »